상심자(Morus alba)의 운동능력 향상과 스트레스 개선효과

Anti-stress and Promoting Effect of the Fruit of Morus alba

  • 황금희 (건국대학교 바이오식의약연구센터)
  • 발행 : 2005.02.28

초록

상심자 추출물이 운동에 의한 체내 monoamine oxidase (MAO) 활성 변화에 미치는 영향을 연구하여. 상심자 추출물을 경구투여(0.3g/kg body weight) 한 흰쥐의 뇌와 간에서 MAO-A와 MAO-B의 활성에 중요한 영향을 미치는 사실을 확인하였다. 각 효소활성은 serotonin과 benzylamine을 기질로 이용하여 측정하였다. 운동 전 후 운동의 유형에 따라 효소활성의 변화경향이 서로 다른 경향을 나타내었다. 뇌에서 측정한 MAO-A 활성은 운동에 의해 효소활성이 현저히 감소하였으며 반면, 간에서 측정한 MAO-B의 활성은 운동이 끝나고 60분이 경과할 때까지 증가된 상태를 유지하고 있었다. 운동 시 체내 변화의 지표효소인 혈중 LDH의 활성 변화와 혈중 lactate의 농도변화를 함께 관찰함으로서 MAO 활성과의 상관관계를 비교하였다. 상심자 추출물을 경구투여 하고 운동을 한 동물의 MAO-A 활성은 증가하였고 MAO-B, LDH 활성과 lactate level은 감소하는 것을 확인하였다. 결과적으로 모은 지표들이 운동 전의 정상상태로 회복되는 것으로 확인되었다. 이 연구의 결과들로부터 상심자 추출물이 운동 전후의 MAO 활성을 조절함으로써 운동능력을 향상시키고 피로를 회복하는 효능을 갖는 것으로 추정되며 이러한 기능성을 갖는 건강기능식품의 소재로 활용이 가능할 것으로 생각한다.

Effects of Morus alba fruit extracts on monoamine oxidase (MAO) activity were examined in rats during and after physical exercise. Oral administration of M. alba extract (0.3 g/kg body weight) significantly increased brain MAO-A activity but decreased liver MAO-B activity when they were measured using serotonin and benzylamine as substrates. Type of physical exercises had significant effect on MAO activity. Brain MAO-A activity markedly decreased with physical activity-related stress compared to normal group, whereas Liver MAO-B activity increased up to 60 min after exercise. Lactate dehydrogenase (LDH) activity and lactate concentration in blood, clinical indices of physical exercise activities, were also determined for correlation to MAO activities. MAO-A activity of rats subjected to oral administration of M. alba extract and physical exercise increased whereas MAO-B and LDH activities, and lactate level decreased, All indices eventually recovered normal levels, These results suggest M. alba may increase capability of physical activities by modulating MAO activities during exercise.

키워드

참고문헌

  1. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. Oxford university press. New York, NY, USA (1996)
  2. Felner AE, Waldmeier PC. Cumulative effects of irreversible MAO inhibitors in vivo. Biochem. Pharmacol. 28: 995-1002 (1979) https://doi.org/10.1016/0006-2952(79)90293-4
  3. Youdim MB, Finberg JP, Tipton KF. Monoamine oxidase. Handbook of Experimental Pharmacology 90: 119-192 (1988)
  4. Sambamoorthi U, Olfson M, Walkup JT, Crystal S. Diffusion of new generation antidepressant treatment among elderly diagnosed with depression. Med. Care. 41: 180-194 (2003) https://doi.org/10.1097/00005650-200301000-00019
  5. Laux G, Philipp M, Kohnen R. Hypertension with moclobemide. Lancet. 347: 1330 (1996)
  6. Silberstein SD. Migraine: preventive treatment. Curr. Med. Res. Opin. 17 (Suppl. 1): s87-93 (2001) https://doi.org/10.1185/0300799039117007
  7. Danisi F. Parkinson's disease. Therapeutic strategies to improve patient function and quality of life. Geriatrics 57: 46-50 (2002)
  8. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 1160: 381-389 (2003)
  9. Sterling J, Herzig Y, Goren T, Finkelstein N, Lerner D, Goldenberg W, Miskolczi I, Molnar S, Rantal F, Tamas T, Toth G, Zagyva A, Zekany A, Lavian G, Gross A, Friedman R, Razin M, Huang W, Krais B, Chorev M, Youdim MB, Weinstock M. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem. 45: 5260-5279 (2002) https://doi.org/10.1021/jm020120c
  10. Brown BR. Treating depression in the HIV-infected patient. HIV Clin. 14: 1-8 (2002)
  11. Stein DJ, Cameron A, Amrein R, Montgomery SA. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int. Clin. Psychopharmacol. 17: 161-170 (2002) https://doi.org/10.1097/00004850-200207000-00002
  12. Bergman J, Yasar S, Winger G. Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors. Psychopharmacology 159: 21-30 (2001) https://doi.org/10.1007/s002130100890
  13. Nowakowska E, Kus K, Chodera A, Rybakowski J. Investigating potential anxiolytic, antidepressant and memory enhancing activity of deprenyl. J. Physiol. Pharmacol. 52: 863-873 (2001)
  14. Hwang KH. Monoamine oxidase inhibitory activities of Korean medicinal plants classified to cold drugs by the theory of KIMI. Food Sci. Biotechnol. 12: 238-241(2003)
  15. Hwang KH, Kim IR, Han YN. Effects of cold and hot drugs on the activity of monoamine oxidase, Korean J. Pharmacogn. 30: 145-150 (1999)
  16. Hwang KH, Song I. The inhibitory activity on MAO of the fruit of Morus Iba. Korean J. Pharmacogn. 34: 185-189 (2003)
  17. Kang BS. Bonchohak 6th ed. Young Lim Sa. Seoul, Korea (2000)
  18. Schwartz MK, Bodansky O. Lactic acid dehydrogenase (clinical aspects). Methods in Enzymology 14: 294-302 (1969)
  19. Jensen PN, Moller HJ, Smith DF, Rosenberg R. Acute effect of exercise on human blood platelet serotonin uptake and monoamine oxidase activity. Biol. Psychiatry. 38: 125-127 (1995) https://doi.org/10.1016/0006-3223(95)00075-R
  20. McEwen CM, Cohen JR, Cohen JD. An amine oxidase in normal human serum. J. Lab. Clin. Med. 62: 766-776 (1963)
  21. Amador E, Dorfman LE, Wacker WEC. Serum lactic dehydrogenase: An analytical assessment of current assays. Clin. Chem. 9: 391-399 (1963)
  22. Barhan D, Trinder P. An improved colour reagent for the determination of blood glucose by oxidase system. Analyst 97: 142-144 (1972) https://doi.org/10.1039/an9729700142
  23. Daniel MB, Stuart JE. Protein Methods. Wiley-Liss, New York, NY, USA (1990)
  24. : SAS User's Guide, Statistics, 6th ed. SAS Institute Inc., Cary, NC, USA (1988)
  25. Hwang KH, Ma JY, Kim IR. The studies on the theory of KIMI by the activity of monoamine oxidase. Korean J. Herbology 14: 1-14 (1999)
  26. Hwang KH, Ma JY, Kim IR. The studies on the theory of KIMI of symptoms by the activity of monoamine oxidase. J. Assoc. Neo Med. 3: 65-74 (1998)